^
    Back
    Association details:
    Biomarker:MYD88 L265P
    Cancer:Waldenstrom Macroglobulinemia
    Drug:Rituxan (rituximab) (CD20 inhibitor) +
    Ninlaro (ixazomib) (Proteasome inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia

    Excerpt:
    ...Overall Response Rate`Progression-free Survival (PFS)`Overall Response Rate by MYD88 L265P and CXCR4-WHIM Status`Time to Progression (TTP)`Duration of Response (DOR)`Time to Next Therapy (TTNT)...
    Trial ID:
    NCT02400437
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Blood Adv
    Title:

    Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up

    Published date:
    08/21/2020
    Excerpt:
    The MYD88 L265P mutation was detected in all patients, and CXCR4 mutations were detected in 15 patients (58%)...The median progression-free survival (PFS) was 40 months, the median duration of response (DOR) was 38 months, and the median time to next treatment (TTNT) was 40 months.
    Secondary therapy:
    dexamethasone
    DOI:
    10.1182/bloodadvances.2020001963